Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more

Recent & Breaking News (NDAQ:VYNE)

SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

PR Newswire November 12, 2019

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

GlobeNewswire November 11, 2019

Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

GlobeNewswire October 31, 2019

Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

GlobeNewswire October 29, 2019

Menlo Therapeutics to Host Investor Day October 29, 2019

GlobeNewswire October 22, 2019

Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

GlobeNewswire October 11, 2019

Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2019

Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

GlobeNewswire September 24, 2019

Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

GlobeNewswire August 29, 2019

Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data

GlobeNewswire August 1, 2019

Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

GlobeNewswire July 31, 2019

Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

Canada NewsWire July 15, 2019

Life Science Company Live Investor Conference July 11th

Canada NewsWire July 9, 2019

Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer

GlobeNewswire June 18, 2019

Menlo Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 29, 2019

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

GlobeNewswire May 13, 2019

Menlo Therapeutics Reports First Quarter 2019 Financial Results

GlobeNewswire May 2, 2019

Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day

GlobeNewswire April 22, 2019

Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis

GlobeNewswire March 25, 2019

Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

GlobeNewswire March 20, 2019